2-(5-Bromo-2-methoxyphenyl)-1,3-dioxane | 121124-95-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2-(5-Bromo-2-methoxyphenyl)-1,3-dioxane
• 英文别名: 2-(3-Bromo-6-methoxyphenyl)-1,3-dioxane
• CAS: 121124-95-6
• 化学式: C₁₁H₁₃BrO₃
• 分子量: 273.126
• InChiKey: QYGXFNAOPHJOMY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  27.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(5-Bromo-2-methoxyphenyl)-1,3-dioxane 在 (+) 三氟甲磺酸三甲基硅酯 、 potassium tert-butylate 、 四丁基氟化铵 、 氢气 、 碳酸氢钠 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 121.0h， 生成 (8S,11S,14S)-14-Benzyloxycarbonylamino-17-methoxy-11-methyl-10,13-dioxo-9,12-diaza-tricyclo[14.3.1.1^2,6]henicosa-1(19),2(21),3,5,16(20),17-hexaene-8-carboxylic acid benzyl ester
  参考文献：
  名称：

  Schmidt, Ulrich; Meyer, Regina; Leitenberger, Volker, Angewandte Chemie, 1989, vol. 101, # 7, p. 946 - 948

  摘要：

  DOI：
• 作为产物：
  描述：

  5-溴-2-甲氧基苯甲醛 、 1,3-丙二醇 在 对甲苯磺酸 碳酸氢钠 、 Brine 、 Sodium sulfate-III 作用下， 以 甲苯 为溶剂， 反应 20.0h， 以to give a brown oil (66.2 g)的产率得到2-(5-Bromo-2-methoxyphenyl)-1,3-dioxane
  参考文献：
  名称：

  Tri-substituted phenyl or pyridine derivatives

  摘要：

  描述了一般式（1）的化合物：其中W-是（1）═C（Y）-，其中Y是卤素原子，或者是烷基或-XRa基团，其中X是-O-，-S（O）m- [其中m为0或值为1或2的整数]，或-N（Rb）- [其中Rb是氢原子或可选地取代的烷基基团]，Ra是氢原子或可选地取代的烷基基团，或（2）═N-; L是（1）-C（R）═C（R1）（R2）或[—CH（R）]nCH（R1）（R2）基团;是（2）-（Xa）nAlk'Ar'，或Alk'XaAr'基团;或（3）XaR1; Z是(A)、(B)、(C)或(D)基团：其中Ar是单环或双环芳基基团，可选地含有从氧、硫或氮原子中选择的一个或多个杂原子；Z1是一个基团-NR12C（O）- [其中R12是氢原子或可选地取代的烷基或（Alk）tAr基团]、-C（O）NR12-、-NR12C(S)-、-C(S)NR12-、-C≡C-、-NR12SO2-或-SO2NR12-；Alk是可选地取代的直链或支链烷基链，可选地由X原子或基团中断；t为0或值为1、2或3的整数；R3是氢或氟原子或可选地取代的直链或支链烷基基团或OR11基团[其中R11是氢原子或可选地取代的烷基、烯基、烷氧基烷基、烷酰基、甲酰基、羧酰胺基或硫代羧酰胺基]；R4是氢原子或可选地取代的烷基、-CO2R8、-CSNR9R10、-CN、-CH2CN或-（CH2）tAr基团，其中t为0或值为1、2或3的整数，Ar是单环或双环芳基基团，可选地含有从氧、硫或氮原子中选择的一个或多个杂原子；但是当L是上述类型（2）或（3）的基团时，Z是类型（A）或类型（B）的基团，其中R4是-（CH2）tAr基团；R5是基团-（CH2）tAr；R6是氢或氟原子，或可选地取代的烷基或-CO2R8、-CONR9R10、-CSNR9R10、-CN或-CH2CN基团；R7是氢或氟原子、可选地取代的直链或支链烷基基团，或ORc基团[其中Rc是氢原子或可选地取代的烷基或烯基基团、烷氧基烷基、烷酰基、甲酰基、羧酰胺基或硫代羧酰胺基]；以及其盐、溶剂化合物、水合物、前药和N-氧化物。本发明的化合物是磷酸二酯酶IV抑制剂，可用于预防和治疗存在不必要的炎症反应或肌肉痉挛的疾病，如哮喘。

  公开号：

  US06245774B1

文献信息

• Substituted benzylaminopiperidine compounds
  申请人：Pfizer Inc.

  公开号：US06329396B1

  公开（公告）日：2001-12-11

  The invention provides a substituted benzylaminopiperidine compounds that are useful in the treatment of gastrointestinal disorders; central nervous system (CNS) disorders; inflammatory disease; emesis; urinary incontinence; pain; migraine; sunburn; diseases, disorders and adverse conditions caused by Heliobacter pylori; or angiogenesis, especially CNS disorders in a mammalian subject, especially in humans.

  这项发明提供了一种取代苄基氨基哌啶化合物，可用于治疗胃肠道疾病；中枢神经系统（CNS）疾病；炎症性疾病；呕吐；尿失禁；疼痛；偏头痛；晒伤；由幽门螺杆菌引起的疾病、疾病和不良症状；或血管生成，尤其是在哺乳动物主体中的中枢神经系统疾病，尤其是在人类中。
• Diamino-functional chalcones
  申请人：Nielsen Feldbaek Simon

  公开号：US20060235073A1

  公开（公告）日：2006-10-19

  The invention provides novel diamino-functionalised chalcone derivatives and analogues thereof. Use of the compounds, or compositions comprising them, as pharmaceutically active agents, in particular against bacterial and parasitic infections, is also disclosed. The invention further relates to a method for detecting inhibitory effects against e.g., bacteria, parasites, fungi, and helminths. The chalcones of the invention carry amino substituents and exhibit enhanced biological effects combined with improved metabolic and physicochemical properties, making the compounds useful as drug substances, in particular as antiparasitic and bacteriostatic agents.

  本发明提供了新型二氨基官能化查尔酮衍生物及其类似物。本发明还揭示了将这些化合物或包含它们的组合物用作药物活性剂，特别是用于对抗细菌和寄生虫感染。本发明还涉及一种检测抑制对细菌、寄生虫、真菌和蠕虫等的影响的方法。本发明的查尔酮具有氨基取代基，并表现出增强的生物效应和改善的代谢和物理化学性质，使这些化合物在药物物质中有用，特别是作为抗寄生虫和抗菌剂。
• Substituted benzylamino piperidine compounds
  申请人：PFIZER INC.

  公开号：EP1114817A1

  公开（公告）日：2001-07-11

  This invention provides a compound of formula (I) and its pharmaceutically acceptable salts wherein R is halo C1-C8 alkyl, halo C2-C8 alkenyl, halo C2-C8 alkynyl or halo C1-C8 alkyl substituted by hydroxy or C1-C8 alkoxy; R1 is hydrogen, halo or C1-C6 alkoxy; or R and R1, together with two carbon atoms shared between the benzene ring and the R and R1, complete a fused C4-C6 cycloakyl wherein one carbon atom is optionally replaced by oxygen and wherein one or two of the carbon atoms are optionally substituted by up to five substituents selected from halo, C1-C6 alkyl and halo C1-C6 alkyl; X is C1-C6 alkoxy, halo C1-C6 alkoxy, phenoxy or halo; and Ar is phenyl optionally substituted by halo. These compounds are of use in treating a gastrointestinal disorder, a central nervous system (CNS) disorder, an inflammatory disease, emesis, urinary incontinence, pain, migraine, sunburn, diseases, disorders and adverse conditions caused by Helicobacter pylori or an angiogenesis especially CNS disorders in a mammalian subject, especially humans.

  本发明提供了式 (I) 的化合物及其药学上可接受的盐类 其中 R 是卤代 C1-C8 烷基、卤代 C2-C8 烯基、卤代 C2-C8 烷炔基或被羟基或 C1-C8 烷氧基取代的卤代 C1-C8 烷基；R1 是氢、卤代或 C1-C6 烷氧基；或 R 和 R1，连同苯环与 R 和 R1 之间共用的两个碳原子，组成一个融合的 C4-C6 环烷基，其中一个碳原子任选被氧取代，并且其中一个或两个碳原子任选被最多五个选自卤代、C1-C6 烷基和卤代 C1-C6 烷基的取代基取代；X 是 C1-C6 烷氧基、卤代 C1-C6 烷氧基、苯氧基或卤代；Ar 是任选被卤代取代的苯基。这些化合物可用于治疗胃肠道疾病、中枢神经系统（CNS）疾病、炎症、呕吐、尿失禁、疼痛、偏头痛、晒伤、幽门螺杆菌引起的疾病、失调和不良状况或血管生成，尤其是哺乳动物，特别是人类的中枢神经系统疾病。
• Synthesis of alkoxy-substituted diaryl compounds and correlation of ring separation with inhibition of tubulin polymerization: differential enhancement of inhibitory effects under suboptimal polymerization reaction conditions
  作者：Zelleka Getahun、Leonard Jurd、Ping S. Chu、Chii M. Lin、Ernest Hamel

  DOI：10.1021/jm00084a011

  日期：1992.3

  A number of cytostatic compounds (2-4, 7, and 8), which can be described as ''diaryl'', inhibit tubulin polymerization, cause cells to accumulate in mitotic arrest, and competitively inhibit the binding of colchicine to tubulin. They differ, however, in the separation of the two aryl moieties. To attempt to understand this variability we prepared a series of analogues modeled on 3 and 4 (''benzodioxole series'') and on 7 and 8 (''combretastatin series'') which differed only in the number of methylene units (ranging from none to four) separating the aryl moieties. These compounds were evaluated for their effects on tubulin polymerization, colchicine binding, and the growth of L1210 murine leukemia cells. In terms of inhibitory effects on tubulin polymerization, for the combretastatin series there was an optimal separation of the two phenyl rings by a two-carbon bridge (compound 24), with progressively decreasing inhibitory activity when the separation was by one carbon (20), three carbons (25), or four carbons (28) (the biphenyl analogue 16 was inactive). The benzodioxole series, however, did not permit us to generalize this finding, because the least active agents prepared (39 and 40) had a two-carbon bridge, while those with one- (5 and 6) and three-carbon (46 and 47) bridges were nearly equivalent in potency. Submicromolar IC50 values for inhibition of L1210 cell growth were only obtained for compounds 20 (IC50, 0.2-mu-M), 24 (0.07-mu-M), and 25 (0.4-mu-M). While evaluating the effects of these agents on tubulin polymerization, we noted with the combretastatin series and with several standard agents that apparent potency (in terms of IC50 values) was always lower if the reaction was performed at 30-degrees-C, with 0.25 mM MgCl2, than at 37-degrees-C, with 1.0 mM MgCl2. This enhancement of IC50 values in the former system as compared with the latter was particularly dramatic for the less active agents (e.g., 28) as compared with the more active (e.g. 24).
• SCHMIDT, ULRICH;MEYER, REGINA;LEITCHBERGER, VOLKER;LIEBERKNECHT, ALBRECHT, ANGEW. CHEM., 101,(1989) N, C. 946-948
  作者：SCHMIDT, ULRICH、MEYER, REGINA、LEITCHBERGER, VOLKER、LIEBERKNECHT, ALBRECHT

  DOI：——

  日期：——